UBS Group AG - DENALI THERAPEUTICS INC ownership

DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 199 filers reported holding DENALI THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.23 and the average weighting 0.3%.

Quarter-by-quarter ownership
UBS Group AG ownership history of DENALI THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$2,263,028
-41.9%
109,696
-16.9%
0.00%0.0%
Q2 2023$3,893,549
+32.7%
131,940
+3.6%
0.00%0.0%
Q1 2023$2,934,167
-12.2%
127,351
+6.0%
0.00%0.0%
Q4 2022$3,342,234
+156.5%
120,181
+183.1%
0.00%0.0%
Q3 2022$1,303,000
+593.1%
42,454
+565.9%
0.00%
Q2 2022$188,000
-85.1%
6,375
-83.7%
0.00%
Q1 2022$1,258,000
-69.5%
39,112
-57.6%
0.00%
-100.0%
Q4 2021$4,119,000
+26.6%
92,348
+43.2%
0.00%0.0%
Q3 2021$3,253,000
+1603.1%
64,480
+2545.9%
0.00%
Q2 2021$191,000
-88.9%
2,437
-91.9%
0.00%
-100.0%
Q1 2021$1,726,000
+255.9%
30,229
+421.5%
0.00%
Q4 2020$485,000
+116.5%
5,796
-7.4%
0.00%
Q3 2020$224,000
+244.6%
6,257
+132.9%
0.00%
Q2 2020$65,000
-68.6%
2,687
-77.2%
0.00%
Q1 2020$207,000
+417.5%
11,808
+411.6%
0.00%
Q4 2019$40,000
-44.4%
2,308
-51.2%
0.00%
Q3 2019$72,000
-19.1%
4,728
+10.8%
0.00%
Q2 2019$89,000
-4.3%
4,269
+6.7%
0.00%
Q1 2019$93,000
-94.3%
4,000
-94.9%
0.00%
-100.0%
Q4 2018$1,622,000
+723.4%
78,485
+766.5%
0.00%
Q3 2018$197,000
+42.8%
9,058
+0.2%
0.00%
Q2 2018$138,000
-35.8%
9,044
-17.2%
0.00%
Q1 2018$215,000
+7066.7%
10,929
+5364.5%
0.00%
Q4 2017$3,0002000.00%
Other shareholders
DENALI THERAPEUTICS INC shareholders Q3 2022
NameSharesValueWeighting ↓
Crestline Management, LP 19,462,500$339,037,00035.95%
Euclidean Capital LLC 323,749$27,117,0005.74%
Flagship Pioneering Inc. 2,730,263$228,687,0004.16%
Casdin Capital, LLC 1,310,000$109,726,0003.25%
A.R.T. Advisors, LLC 6,173$517,0002.39%
MARK ASSET MANAGEMENT LP 172,040$14,410,0001.73%
Temasek Holdings (Private) Ltd 4,410,457$369,420,0001.59%
Integral Health Asset Management, LLC 57,500$4,816,0001.43%
GILDER GAGNON HOWE & CO LLC 3,219,843$269,694,0001.34%
IRONWOOD INVESTMENT MANAGEMENT LLC 19,365$1,622,0000.95%
View complete list of DENALI THERAPEUTICS INC shareholders